Phase 1 (Safety and Dosage)

Phase 1 clinical trials for psychiatric or CNS-targeting drugs come with unique challenges. These compounds may affect mood, cognition, or behavior even at sub-therapeutic doses, requiring sensitive and sophisticated safety assessments. Whether developing treatments for depression, schizophrenia, anxiety, or neurodevelopmental disorders, early-phase studies must go beyond traditional PK/PD and incorporate neuropsychiatric monitoring, abuse potential screening, and psychometric tools. This article provides a roadmap for Phase 1 trial design in psychiatric drug development.
Click to read the full article.

As drug development becomes increasingly global, sponsors must navigate differing regulatory frameworks when planning Phase 1 trials across regions. While there is general alignment through ICH guidelines, specific requirements for study design, safety monitoring, documentation, and subject protection vary among the US (FDA), EU (EMA), Japan (PMDA), and India (CDSCO). This article outlines key differences and emerging efforts in global harmonization of Phase 1 clinical trials.
Click to read the full article.

Traditionally, real-world data (RWD) has been associated with post-marketing studies or Phase 4 evidence generation. But in recent years, sponsors have started to leverage RWD much earlier—during Phase 1 or even preclinical stages. By integrating electronic health records (EHRs), insurance claims, registries, and digital health sources, developers can make more informed decisions about trial design, safety markers, patient selection, and unmet needs. This article explores how RWD is reshaping early clinical development and offers strategies for its effective use in Phase 1 trials.
Click to read the full article.

Phase 1 trials rely on dose-escalation studies to determine the optimal range for safety and pharmacokinetics (PK). In small cohorts—often 3 to 6 subjects per group—traditional statistical power does not apply. Instead, developers use adaptive designs, Bayesian modeling, and real-time decision algorithms to ensure efficient dose escalation with minimal risk. This article outlines the key statistical frameworks used in small-cohort Phase 1 studies and how they influence decision-making, stopping rules, and maximum tolerated dose (MTD) estimation.
Click to read the full article.

Recruitment speed and subject retention are critical success factors in Phase 1 clinical trials. Dedicated Phase 1 Units and established healthy volunteer databases play a central role in improving operational efficiency. These infrastructures not only accelerate screening and enrollment but also provide a controlled environment for safety monitoring, data consistency, and protocol adherence. This article highlights how these systems support early-phase trial success and outlines global best practices.
Click to read the full article.

Phase 1 clinical trials are foundational to drug development. They are rich with specialized terminology spanning pharmacokinetics, safety monitoring, statistics, and regulatory science. This glossary provides concise definitions of scientific terms and acronyms commonly used in Phase 1 trials, helping students, clinicians, and professionals build a solid understanding of early-phase research.
Click to read the full article.